Innovative Medicines (IMI);

This procedure concerns the European Parliament's approval of how the Innovative Medicines Initiative (IMI) managed its budget in 2010. It's part of the annual scrutiny of EU bodies' financial activities.

This decision affects the IMI and its partners, ensuring accountability in public spending and the effective use of funds for research and innovation in medicine.